EMD Serono Appoints New Leaders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMD Serono Appoints New Leaders



EMD Serono, a subsidiary of Merck KGaA, reported the appointments of Gary Zieziula as COO, Allene Diaz as senior vice-president of Managed Markets, Lisa Buffington as vice-president of US Communications, Alexander Kuta as vice-president and head of US Regulatory Affairs, and Michael Ruggiero as vice-president of US Government Affairs and Policy.

Zieziula is responsible for increasing the growth of the US organization by controlling the performance of EMD franchises.

Diaz is responsible for developing and executing Managed Markets marketing, sales, and contracting strategies for EMD Seronoproducts.

Buffington is responsible for executing all aspects of the company’s communications strategy, including external and employee communications, media relations, corporate reputation, product communications, community relations, as well as meetings and events.

Kuta is responsible for the strategic direction of EMD Serono’s regulatory efforts with the FDA, overseeing regulatory submissions in the US and strengthening interactions with the FDA.

Ruggiero is responsible for federal and state legislative, policy, political, and advocacy strategy and execution for EMD Serono’s business.

Source: EMD Serono

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here